Recombinant erythropoietin as treatment for the late hyporegenerative anemia of Rh hemolytic disease

Pediatrics. 1992 Nov;90(5):678-80.

Abstract

Infants with Rh hemolytic disease can develop a "late" anemia characterized by low serum concentrations of erythropoietin but erythroid progenitors that remain highly erythropoietin-responsive. Erythropoietin administration was evaluated in two patients as an alternative to transfusion. Reticulocyte counts increased after 5 days of treatment, and hematocrits increased after 10 days. Neither patient received erythrocyte transfusions following erythropoietin therapy.

Publication types

  • Case Reports
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anemia, Hemolytic / blood
  • Anemia, Hemolytic / drug therapy*
  • Anemia, Hemolytic / etiology
  • Bone Marrow Examination
  • Erythropoietin / therapeutic use*
  • Humans
  • Infant
  • Male
  • Recombinant Proteins / therapeutic use
  • Rh Isoimmunization / blood
  • Rh Isoimmunization / complications*

Substances

  • Recombinant Proteins
  • Erythropoietin